Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills
FRIDAY, May 16, 2025 (HealthDay News) — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases. The deal could be worth up to $2.2 billion for Septerna. This includes more than $200 million inContinue Reading